Predictors of stroke in high-risk patients after acute myocardial infarction: Insights from the VALIANT trial

European Heart Journal

Volumn 28, Issue 6, 2007, Pages 685-691

  Sampson, Uchechukwu K ^a   Pfeffer, Marc A ^a   McMurray, John J V ^b   Lokhnygina, Yuliya ^c   White, Harvey D ^d   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WESTERN INFIRMARY   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Acute cerebral haemorrhage; Acute cerebral infarction; Acute coronary syndromes; Acute myocardial infarction; Embolic stroke; Risk factors for stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CAPTOPRIL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; VALSARTAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SEX RATIO; SINUS RHYTHM; STROKE;

AGED; BRAIN INFARCTION; CEREBRAL HEMORRHAGE; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; STROKE;

EID: 33947315417     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl197     Document Type: Article

References (25)

1. Hess DC, D'Cruz IA, Adams RJ, Nichols FT III. Coronary artery disease, myocardial infarction, and brain embolism. Neurol Clin 1993;11:399-417.
2. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997;29:1074-1080.
3. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
4. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000;54:288-294.
5. Szummer KE, Solomon SD, Velazquez EJ, Kilaru R, McMurray J, Rouleau JL, Mahaffey KW, Maggioni AP, Califf RM, Pfeffer MA, White HD. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. Eur Heart J 2005;26: 2114-2119.
6. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van De Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-750.
7. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both inmyocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
8. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285- 1295.
9. Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-380.
10. Kiely DK, Wolf PA, Cupples LA, Beiser AS, Myers RH. Familial aggregation of stroke. The Framingham Study. Stroke 1993;24:1366-1371.
11. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 1997;28:1507-1517.
12. Mohr JP, Albers GW, Amarenco P, Babikian VL, Biller J, Brey RL, Coull B, Easton JD, Gomez CR, Helgason CM, Kase CS, Pullicino PM, Turpie AG. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Etiology of stroke. Stroke 1997;28:1501-1506.
13. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAuley CM, Lincoff AM, Decekrs J, Topol EJ, Califf RM. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 1999;99:2371-2377.
14. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995- 1003.
15. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
16. Culman J, Blume A, Gohlke P, Unger T. The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers. J Hum Hypertens 2002;16:S64-S70.
17. Steckelings UM, Kaschina E, Unger T. The AT2 receptor - a matter of love and hate. Peptides 2005;26:1401-1409.
18. Thone-Reineke C, Zimmerman M, Neumann C, Krikov M, Li J, Gerova N, Unger T. Are angiotensin receptor blockers neuroprotective? Curr Hypertens Rep 2004;6:257-266.
19. Wilms H, Rosenstiel P, Unger T, Deuschl G, Lucius R. Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs 2005;5:245-253.
20. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hillbrich L, Pogue J, Schumacher H. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52-61.
21. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
22. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-950.
23. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305- 1310.
24. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 1999;99:216-223.
25. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997;28:2315-2320.